Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.48 |
| ▸ | DHFR | P00374 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20440744 | 1.00 | SLC6A3 (0.48) | SLC6A3SLC6A2SLC6A4DHFRHTR2C | |
| SCHEMBL20439204 | 1.00 | SLC6A3 (0.48) | SLC6A3SLC6A2SLC6A4DHFRHTR2C | |
| SCHEMBL20439271 | 1.00 | SLC6A3 (0.48) | SLC6A3SLC6A2SLC6A4DHFRHTR2C | |
| SCHEMBL24507808 | 0.81 | SLC6A3 (0.46) | SLC6A3SLC6A2SLC6A4DHFRTSHR | |
| SCHEMBL24507809 | 0.81 | SLC6A3 (0.46) | SLC6A3SLC6A2SLC6A4DHFRTSHR | |
| SCHEMBL24507968 | 0.80 | SLC6A3 (0.46) | SLC6A3SLC6A2SLC6A4DHFRTSHR | |
| SCHEMBL23759215 | 0.80 | SLC6A3 (0.46) | SLC6A3SLC6A2SLC6A4DHFRTSHR | |
| SCHEMBL10092294 | 0.80 | SLC6A3 (0.47) | SLC6A3SLC6A2SLC6A4DHFRTSHR | |
| SCHEMBL23759216 | 0.80 | SLC6A3 (0.46) | SLC6A3SLC6A2SLC6A4DHFRTSHR | |
| Hydrochloric Acid SCHEMBL30408670 | 0.79 | SLC6A3 (0.48) | SLC6A3SLC6A2SLC6A4DHFRTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11634710-B2 | Oligonucleotide compositions and methods thereof | WAVE LIFE SCIENCES LTD. (SG) | 2023-04-25 | — | — | US | disclosed |
| US-20220186217-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2022-06-16 | — | — | US | disclosed |
| US-20220162598-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2022-05-26 | — | — | US | disclosed |
| US-20210254062-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2021-08-19 | — | — | US | disclosed |
| US-20200299692-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2020-09-24 | — | — | US | disclosed |
| US-10724035-B2 | Oligonucleotide compositions and methods thereof | WAVE LIFE SCIENCES LTD. (SG) | 2020-07-28 | — | — | US | disclosed |
| US-20200056173-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2020-02-20 | — | — | US | disclosed |
| US-10479995-B2 | Oligonucleotide compositions and methods thereof | WAVE LIFE SCIENCES LTD. (SG) | 2019-11-19 | — | — | US | disclosed |
| WO-2019217784-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2019-11-14 | — | — | WO | disclosed |
| US-20180216108-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2018-08-02 | — | — | US | disclosed |
| EP-0981526-B1 | NOVEL ANTIDIABETIC COMPOUNDS HAVING HYPOLIPIDAEMIC, ANTIHYPERTENSIVE PROPERTIES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | REDDYS LAB LTD DR (IN) | 2004-02-25 | — | — | EP | disclosed |
| CN-1221415-A | Novel antidiabetic compounds having hypolipidemic and antihypertensive properties, process for their preparation and pharmaceutical compositions containing them | REDDY RESEARCH FOUNDATION (IN) | 1999-06-30 | — | — | CN | disclosed |
| US-5889025-A | Antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them | REDDY'S RESEARCH FOUNDATION (IN) | 1999-03-30 | — | — | US | disclosed |
| US-5559242-A | FROM PYROGLUTAMIC ACID, ESTERIFICATION, REACTION WITH DIANION OF ACETONE OXIME, CYCLIZATION, REDUCTION, ALKYLATION | ABBOTT LABORATORIES (US) | 1996-09-24 | — | — | US | disclosed |
| EP-0717741-A1 | METHOD OF PREPARING ENANTIOMERICALLY-PURE 3-METHYL-5-(1-ALKYL-2(S)-PYRROLIDINYL)ISOXAZOLES | ABBOTT LABORATORIES (US) | 1996-06-26 | — | — | EP | disclosed |
| US-5516912-A | FROM PROTECTED 2-OXOPYRROLIDINE | ABBOTT LABORATORIES (US) | 1996-05-14 | — | — | US | disclosed |
| US-5508418-A | FOR MAKING CHOLINERGIC OR ANXIOLYTIC AGENTS | ABBOTT LABORATORIES (US) | 1996-04-16 | — | — | US | disclosed |
| US-5424444-A | Reacting N-alkyl-L-proline ester with salt of dianion of acetone oxime or acetonitrile or other imine anion compounds; cyclization, dehydration after reaction with Grignard reagent and hydroxylamine | ABBOTT LABORATORIES (US) | 1995-06-13 | — | — | US | disclosed |
| WO-1995007277-A1 | METHOD OF PREPARING ENANTIOMERICALLY-PURE 3-METHYL-5-(1-ALKYL-2(S)-PYRROLIDINYL)ISOXAZOLES | ABBOTT LABORATORIES (US) | 1995-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299692-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RBM17, HNRNPA2B1, HNRNPA1 | SLC6A3 3033/4885SLC6A2 2680/4885SLC6A4 2642/4885 |
| US-10479995-B2 | Oligonucleotide compositions and methods thereof | RNGTT, NSUN2, POLRMT | SLC6A3 4437/4885SLC6A2 4690/4885SLC6A4 3944/4885 |
| US-11634710-B2 | Oligonucleotide compositions and methods thereof | RBM17, HNRNPA2B1, HNRNPA1 | SLC6A3 3033/4885SLC6A2 2680/4885SLC6A4 2642/4885 |
| US-20180216108-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RNGTT, NSUN2, POLRMT | SLC6A3 4437/4885SLC6A2 4690/4885SLC6A4 3944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.